CXCL1 and dysplasia: After including sVEGRF3, GRO and CRP (the immune‐related markers associated with current use of NSAIDS) in the model, the association between NSAID use and dysplasia was attenuated (OR: 0.79, 95% CI: 0.36–1.68).